Newsroom Articles

Beth’s recognition reflects more than 25 years of leadership at Ionis. As a member of the executive leadership team, she has helped guide the company’s transformation from an organization focused primarily on research and early development into a fully integrated commercial-stage biotech.

When triglyceride levels reach 500 mg/dL or higher, the risks of serious complications like acute pancreatitis and atherosclerotic cardiovascular disease can increase. Watch as people living with sHTG share their experiences and reveal the often-misunderstood realities of living with this serious condition.

Advances in science and treatment are changing how severe hypertriglyceridemia (sHTG) is identified and managed. Here are four trends helping shape the future of care.

Ionis has been recognized as one of the San Diego Business Journal's Best Places to Work for the third consecutive year. This year, Ionis ranked #3 in the Large Company category, climbing three spots from #6 in 2025.

Explore Yajaira's journey with severe hypertriglyceridemia (sHTG), including the risks of high triglycerides, pancreatitis, and the importance of early awareness.

March marks Amyloidosis Awareness Month. We sat down with Charles, an 88-year-old retired cardiologist from Massachusetts, who shared what it’s like to diagnose and treat heart disease for decades and then face a diagnosis himself. His experience with transthyretin amyloid cardiomyopathy (ATTR-CM) offers a unique perspective on this underrecognized condition.

Rick has experienced symptoms of FCS his entire life. He has been hospitalized more times than he can count with acute pancreatitis and describes it as the most pain he has ever been in. Despite these challenges, Rick is hopeful about the future for people living with this rare and severe disease and passionate about helping other people with FCS.

Recognizing our industry-leading scientific innovation and company culture, Science magazine ranked Ionis their #2 Top Employer in 2025.

In celebration of Brett Monia, Ph.D., recipient of the 2025 Oligonucleotide Therapeutics Society (OTS) Lifetime Achievement Award, colleagues and peers reflect on his extraordinary impact on science, leadership and patient care.

Hear Dr. Sam Tsimikas, SVP of Global Cardiovascular Development, share how Ionis is redefining cardiometabolic care.

Endpoints News honors Ionis’ Holly Kordasiewicz, Ph.D., SVP, Neurology for her leadership, scientific impact and commitment to advancing diversity in biopharma

Ionis is proud to announce that we have ranked #6 on the San Diego Business Journal’s 2025 Best Places to Work list in the Large Companies category. This marks our second consecutive year being recognized and our first year breaking into the Top 10…